Table 1 Clinical baseline characteristics of the participants
Parameter | Total (n = 11) | Responder (n = 8) | Non-responder (n = 3) |
|---|---|---|---|
Gender | |||
Female | 7 (64%) | 5 (62%) | 2 (67%) |
Male | 4 (36%) | 3 (38%) | 1 (33%) |
Age | 33.6 ± 10.5 | 29.6 ± 9.2 | 44.3 ± 8.0 |
(19.0 to 55.0) | (19.0 to 47.0) | (39.0 to 55.0) | |
Body mass index | 25.5 ± 3.0 | 22.9 ± 2.6 | 26.2 ± 4.0 |
(20.1 to 30.7) | (22.0 to 30.7) | (20.1 to 25.7) | |
Relapse rates in the past 12 months (median and range) | 2 | 2 | 1 |
(1 to 4) | (1 to 4) | (1 to 2) | |
Baseline Expanded Disability Status Scale | 4 | 3.5 | 4 |
(2 to 7.5) | (2 to 7.5) | (3 to 4) | |
Days after onset of relapse | 26.6 ± 14.6 | 29.3 ± 15.6 | 19.3 ± 10.1 |
(10.0 to 60.0) | (10.0 to 60.0) | (10.0 to 30.0) | |
Days after initiation of corticosteroid therapy | 10.8 ± 6.9 | 12.3 ± 6.6 | 7.0 ± 7.2 |
(1.0 to 20.0) | (3.0 to 20.0) | (1.0 to 15.0) | |
Cumulative dose of prednisolone equivalents (g) | 9.5 ± 3.7 | 8.6 ± 3.7 | 12.0 ± 2.6 |
(4.0 to 15.0) | (4.0 to 15.0) | (10.0 to 15.0) | |
Duration of disease (years) | 3.5 ± 4.9 | 5.7 ± 2.9 | 2.7 ± 9.0 |
(0.0 to 16.0) | (0 to 7.0) | (0.0 to 16.0) | |
Initial disease modifying therapy | 3 (27.3%) | 2 (25%) | 1 (33.3%) |
Interferon beta | 2 (18.2%) | 2 (25%) | 0 (0%) |
Glatiramer acetate | 1 (9.1%) | 0 (0%) | 1 (33.3%) |